Information Provided By: 
Fly News Breaks for August 7, 2019
BHC
Aug 7, 2019 | 07:38 EDT
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Bausch Health Companies to $54 from $50 following the company's Q2 results and reiterates a Buy rating on the shares. Bausch delivered "healthy" gross margins of 73% for the first half of 2019, and expects a 72% gross margin rate for the full year, Selvaraju tells investors in a research note. He believes the company's flagship Bausch + Lomb division "continues to perform robustly."
News For BHC From the Last 2 Days
